Contineum Therapeutics Inc (CTNM)

04:41 AM

Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - marketbeat.com

04:41 AM

Aug 14, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com

Aug 14, 2026

Aug 14, 2026

Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan

Aug 14, 2026

Aug 13, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - marketbeat.com

Aug 13, 2026

Aug 06, 2026

(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria

Aug 03, 2026

Aug 03, 2026

Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria

Aug 03, 2026

Aug 03, 2026

Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan

Aug 03, 2026

Aug 03, 2026

CTNM (CTNM) insider schedules 2,500-share stock sale after recent 10b5-1 trades - Stock Titan

Aug 03, 2026

Aug 03, 2026

CTNM (CTNM) insider Daniel Lorrain files to sell 9,520 common shares - Stock Titan

Aug 03, 2026

Aug 03, 2026

Contineum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 03, 2026

Aug 02, 2026

Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM - marketbeat.com

Aug 02, 2026

Aug 01, 2026

RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail

Aug 01, 2026

Jul 31, 2026

RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com

Jul 31, 2026

Jul 30, 2026

Contineum reports $15.2 million second quarter loss - Quiver Quantitative

Jul 30, 2026

Jul 30, 2026

Contineum Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView

Jul 30, 2026

Jul 30, 2026

Contineum Therapeutics reports Q2 2026 net loss $15.2M; cash and marketable securities $236.6M - TradingView

Jul 30, 2026

Jul 30, 2026

CTNM|Contineum Therapeutics Inc|Price:15.040|Chg%:-0.310 - TradingKey

Jul 30, 2026

Jul 28, 2026

Contineum Therapeutics, Inc. Revenue Breakdown – NASDAQ:CTNM - TradingView

Jul 28, 2026

Jul 27, 2026

BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc - Stock Titan

Jul 27, 2026

Jul 27, 2026

CTNM|Contineum Therapeutics Inc|Price:15.390|Chg%:-0.510 - TradingKey

Jul 27, 2026

Jul 26, 2026

Contineum Therapeutics Inc (CTNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 26, 2026

Jul 26, 2026

Contineum Therapeutics Inc (CTNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026

Jul 26, 2026

Contineum Therapeutics Inc (CTNM) Institutional Confidence - TradingKey

Jul 26, 2026

Jul 26, 2026

Contineum Therapeutics Inc (CTNM) Balance Sheet - TradingKey

Jul 26, 2026

Jul 25, 2026

Contineum Therapeutics Market Sentiment - Benzinga España

Jul 25, 2026

Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026

Jul 25, 2026

Contineum Therapeutics Inc (CTNM) Income Statement - TradingKey

Jul 25, 2026

Jul 25, 2026

CTNM|Contineum Therapeutics Inc|Price:13.835|Chg%:-0.225 - TradingKey

Jul 25, 2026

Jul 23, 2026

Millennium Management LLC Reduces Stake in Contineum Therapeutics Inc - GuruFocus

Jul 23, 2026

Jul 20, 2026

Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise, Stock Pulls BackEPS Growth Rate - dars.gov.et

Jul 20, 2026

Jul 18, 2026

Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN

Jul 18, 2026

Jul 17, 2026

Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update - Stock Titan

Jul 17, 2026

Jul 17, 2026

Contineum Therapeutics (NASDAQ:CTNM) Is In A Good Position To Deliver On Growth Plans - Moomoo

Jul 17, 2026

Jul 17, 2026

Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis - Kalkine

Jul 17, 2026

Jul 15, 2026

Liquidity Mapping Around (CTNM) Price Events - Stock Traders Daily

Jul 15, 2026

Jul 14, 2026

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership - The Globe and Mail

Jul 14, 2026

Jul 13, 2026

Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029 - TradingView

Jul 13, 2026

Jul 13, 2026

Contineum Therapeutics (NASDAQ: CTNM) details PIPE-791 IPF trial and PIPE-307 deal - Stock Titan

Jul 13, 2026

Jul 13, 2026

CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressRevenue Beat Analysis - dars.gov.et

Jul 13, 2026

Jul 12, 2026

Contineum Therapeutics (CTNM) Slips Amidst Sector Pressures – Key Levels in FocusCash Flow Strong Stocks - dars.gov.et

Jul 12, 2026

Jul 10, 2026

Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock - Investing.com UK

Jul 10, 2026

Jul 10, 2026

Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com - Investing.com Nigeria

Jul 10, 2026

Jul 10, 2026

Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria

Jul 10, 2026

Jul 10, 2026

Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options - Stock Titan

Jul 10, 2026

Jul 09, 2026

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - MSN

Jul 09, 2026

Jul 08, 2026

Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Jul 08, 2026

Contineum Therapeutics CEO Stengone sells $40,000 in shares By Investing.com - Investing.com South Africa

Jul 08, 2026

Jul 08, 2026

Price to sales forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView

Jul 08, 2026

Jul 08, 2026

Contineum Therapeutics CEO Stengone sells $40,000 in shares - Investing.com

Jul 08, 2026